13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
198 檔
7.7%
In Q1 2025, ADAR1 Capital Management, LLC's U.S. equity holdings reached a combined market value of $2.2B, distributed across 198 disclosed stock positions.
During Q1 2025, ADAR1 Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 8.44% | -0.78% | -18.46% | |
| 2 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 6.98% | -0.50% | +3.59% | |
| 3 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.52% | -0.25% | -0.72% | |
| 4 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 6.31% | +1.35% | -10.04% | |
| 5 | IMVT | Immunovant Inc | Stock-Other | 3.07% | +0.19% | +23.03% | |
| 6 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.92% | -0.66% | -8.99% | |
| 7 | KROS | Keros Therapeutics Inc | Stock-Other | 2.81% | +0.06% | +6294.48% | |
| 8 | ABVX | Abivax Sa-adr | Stock-Other | 2.56% | +1.85% | +46.03% | |
| 9 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 2.31% | -0.16% | +2.88% | |
| 10 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.18% | +0.19% | -49.97% | |
| 11 | JANX | Janux Therapeutics Inc | Stock-Other | 2.10% | +0.06% | +1228.72% | |
| 12 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 2.08% | +0.04% | +0.37% | |
| 13 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.83% | — | — | |
| 14 | SHY | Ishares 1-3 Year Treasury Bo | ETF-Gov Bonds | 1.59% | — | — | |
| 15 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 1.49% | -0.05% | +257.10% | |
| 16 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.46% | +0.26% | +207.29% | |
| 17 | ✓ | Stock-Other | 1.43% | +0.02% | — | ||
| 18 | CGON | Cg Oncology Inc | Stock-Other | 1.37% | -0.35% | +39.58% | |
| 19 | ✓ | Rapt Therapeutics Inc | Stock-Other | 1.35% | — | +408.45% | |
| 20 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.22% | -0.55% | +20.86% | |
| 21 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.18% | — | — | |
| 22 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.16% | -0.02% | +4.20% | |
| 23 | AVR | Anteris Technologies Global | Stock-Other | 1.13% | +0.18% | +59.37% | |
| 24 | YCY-UN | AA Mission Acquisition Corp. II | Stock-Other | 1.12% | — | +3.24% | |
| 25 | SG7 | Sage Therapeutics Inc | Stock-Other | 1.10% | — | +3767.16% | |
| 26 | ETNBGBP | 89bio Inc | Stock-Other | 1.09% | — | +56.12% | |
| 27 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 1.03% | — | — | |
| 28 | CHRS 1.5 04-15-26Bond | Coherus Oncology Inc | Bond | 1.02% | — | — | |
| 29 | ✓ | Stock-Other | 1.00% | -0.06% | +3.30% | ||
| 30 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.99% | — | +16.23% | |
| 31 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.97% | -0.38% | +14615.87% | |
| 32 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.94% | -1.18% | EXIT | |
| 33 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.91% | -0.09% | EXIT | |
| 34 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.79% | -0.32% | +152.34% | |
| 35 | XNCR | Xencor Inc | Stock-Other | 0.79% | +0.10% | +69.71% | |
| 36 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.78% | +0.12% | -68.70% | |
| 37 | SEPN | Septerna Inc | Stock-Other | 0.77% | -0.10% | — | |
| 38 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | Bond | 0.75% | -0.06% | — | |
| 39 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.73% | +0.19% | NEW | |
| 40 | SVRA | Savara Inc | Stock-Other | 0.70% | -0.07% | +37.62% | |
| 41 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.68% | +0.07% | -22.50% | |
| 42 | ✓ | Stock-Other | 0.68% | — | +57.46% | ||
| 43 | BIOA | Bioage Labs Inc | Stock-Other | 0.68% | -0.14% | EXIT | |
| 44 | ✓ | Zura Bio LTD | Stock-Other | 0.67% | +0.26% | +34.85% | |
| 45 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.64% | — | +605.28% | |
| 46 | RZLT | Rezolute Inc | Stock-Other | 0.60% | — | -17.89% | |
| 47 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.58% | -0.09% | EXIT | |
| 48 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.53% | — | +88.17% | |
| 49 | ✓ | Merus N V | Stock-Other | 0.52% | — | -17.80% | |
| 50 | ✓ | Bridgebio Pharma Inc | Stock-Other | 0.51% | — | — |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 198 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, BOXX, ROIV) accounted for 7.7% of total reported equity market value during Q1 2025.
During Q1 2025, ADAR1 Capital Management, LLC's top holdings by market value included PTGX (8.4%)、BOXX (7.0%)、ROIV (6.5%). The largest single position, PTGX, represented 8.4% of total portfolio value.
In Q1 2025, ADAR1 Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.